Skip to content
TrialScanner

NCT05263050

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Phase 2RecruitingEXELCollaborator

Registry record

Lead sponsor
Fox Chase Cancer Center
Conditions
Metastatic Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma; Neuroendocrine Tumors; Carcinoid Tumor
Primary completion
Dec 2026Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT05263050 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05263050: Trial of an Alternative... | TrialScanner